Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

517 ARTÍCULOS , VIENDO DEL 346 AL 360

Plasma Aβ biomarker for early diagnosis and prognosis of Alzheimer's disease - a systematic review

Ebbesen SU, Høgh P, Zibrandtsen I.

Dan Med J. 2023 May 10;70(6):A07220446.

Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo

Therriault J, Gauthier S, Rosa-Neto P.

J Prev Alzheimers Dis. 2023;10(3):381-386. doi: 10.14283/jpad.2023.52.

Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias

Hu WT, Nayyar A, Kaluzova M.

Neurotherapeutics. 2023 Jul;20(4):955-974. doi: 10.1007/s13311-023-01370-8. Epub 2023 Jun 28.

Predicting cognitive decline in older people by structural and molecular imaging

Teipel S, Tang Y, Boccardi M.

Curr Opin Neurol. 2023 Aug 1;36(4):253-263. doi: 10.1097/WCO.0000000000001172. Epub 2023 Jun 19.

MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease

Filippi M, Cecchetti G, Agosta F.

Curr Opin Neurol. 2023 Aug 1;36(4):239-244. doi: 10.1097/WCO.0000000000001177. Epub 2023 Jun 23.

Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers

Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D.

Curr Opin Neurol. 2023 Aug 1;36(4):264-275. doi: 10.1097/WCO.0000000000001173. Epub 2023 Jun 9.

A review of neuroimaging-based data-driven approach for Alzheimer's disease heterogeneity analysis

Liu L, Sun S, Kang W, Wu S, Lin L.

Rev Neurosci. 2023 Jul 10;35(2):121-139. doi: 10.1515/revneuro-2023-0033. Print 2024 Feb 26.

Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials

Rahman-Filipiak A, Bolton C, Grill JD, Rostamzadeh A, Chin N, Heidebrink J, Getz S, Fowler NR, Rosen A, Lingler J, Wijsman E, Clark L; Advisory Group on Risk Evidence Education in Dementia (AGREED).

Alzheimers Dement. 2023 Sep;19(9):4270-4275. doi: 10.1002/alz.13380. Epub 2023 Jul 14.

PET Radiomics of White Matter, Can Be Employed as a Biomarker to Identify the Progression of Mild Cognitive Impairment to Alzheimer's Disease

Chen F.

Acad Radiol. 2023 Sep;30(9):1885-1886. doi: 10.1016/j.acra.2023.06.020. Epub 2023 Jul 17.

Impact of sharing Alzheimer's disease biomarkers with individuals without dementia: A systematic review and meta-analysis of empirical data

van der Schaar J, Visser LNC, Ket JCF, Groot C, Pijnenburg YAL, Scheltens P, Bredenoord AL, van den Hoven MA, van der Flier WM.

Alzheimers Dement. 2023 Dec;19(12):5773-5794. doi: 10.1002/alz.13410. Epub 2023 Jul 26.

The performance of plasma phosphorylated tau231 in detecting Alzheimer's disease: A systematic review with meta-analysis

Xu C, Zhao L, Dong C.

Eur J Neurosci. 2023 Aug;58(4):3132-3149. doi: 10.1111/ejn.16085. Epub 2023 Jul 27.

Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer's Disease

Sharma A, Angnes L, Sattarahmady N, Negahdary M, Heli H.

Biosensors (Basel). 2023 Jul 17;13(7):742. doi: 10.3390/bios13070742.

Neurofilament Light Chain as a Potential Biomarker in Plasma for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis

Fan Z, Liu X, Liu J, Chen C, Zhou M.

J Integr Neurosci. 2023 Jun 30;22(4):85. doi: 10.31083/j.jin2204085.

Tear biomarkers for Alzheimer's disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study

van de Sande N, Ramakers IHGB, Visser PJ, Verhey FRJ, Verbraak FD, Bouwman FH, Berendschot TTJM, Nuijts RMMA, Webers CAB, Gijs M.

BMC Neurol. 2023 Aug 5;23(1):293. doi: 10.1186/s12883-023-03335-y.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias